Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. METHODS: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. RESULTS: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1-0.4 mg/kg i.v., and another assessed 0.1-0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6-7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2-5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. CONCLUSION: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine, a glutamatergic agent used routinely for induction and maintenance of anesthesia, exhibits well-replicated, rapid, potent antidepressant effects in randomized controlled trials (i.e., metaanalytic Cohen's d=1.4, a large effect) 12 , even in difficult-to-treat conditions such as treatment-resistant depression 32 and bipolar depression 33 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Approach: Intravenous ketamine Evidence: Strong support 12”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As an example, we discuss the potential for ketamine-which exhibits both rapid plasticity-enhancing effects in animal models 4,10 and rapid clinical effects in human patients 11,12 -to provide a test of the predictions of this integrative model, including simultaneous and correlated reversals of multiple plasticity-related deficits across levels of analysis.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundRetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 4×
“The primary endpoint was change in depression severity scores from baseline on depression scales such as the Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and/or the Montgomery Åsberg Depression Rating Scale [MADRS]) at the following times: day 1 (24 hours after first dose), day 3, and day 7.”
MethodInfluentialCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 3×
“The I2 statistic was used to assess heterogeneity of trial results, and subgroup heterogeneity was tested using a chi-squared statistic (Higgins and Green, 2009).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 8×
“The results showed that Visual Analogue Scale score for intoxication “high” scores returned to baseline within 110 minutes of the infusion (Berman et al., 2000).”
BackgroundMethodResultInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Several additional strands of evidence indicate that the benefit observed in these trials is a result of depression treatment, rather than nonspecific mood elevation or a ‘high’ following ketamine administration: there is improvement in core depressive symptoms such as sadness, suicidality, and helplessness; the time…”
BackgroundAitken, R. C. B. (1969) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576906201005 · Cited by 1,539 · cited 2×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al.”
MethodMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 13×
“…2000; Zarate et al., 2006, 2012; Diazgranados et al., 2010a; Sos et al., 2013; Lai et al., 2014; Lapidus et al., 2014) used 0.9% saline as placebo and 2 used 0.045 mg/kg (Murrough et al., 2013) or 0.01 mg/kg (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data) midazolam as an active placebo.”
BackgroundMethodInfluentialWhiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175 · cited 1×
“Recent trials have also suggested possible benefits among patients with posttraumatic stress disorder (Whiteford et al., 2015) and in obsessive compulsive disorder (Rodriguez et al.”
BackgroundDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 9×
“Also, while not reported as serious adverse events, one ketaminetreated patient developed manic symptoms that resolved within 80 minutes, and an affective switch occurred for one patient in the placebo group (Diazgranados et al., 2010a).”
BackgroundMethodInfluentialBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817 · cited 2×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 7×
“In the 2 trials among patients with BD, the treatment effect largely dissipated by days 4 to 7 (Diazgranados et al., 2010a; Zarate et al., 2012).”
BackgroundMethodResultInfluentialCross-Over Trials in Clinical Research
(1994) · Technometrics · doi:10.1080/00401706.1994.10485798 · Cited by 763
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690 · cited 1×
“…et al., 2006; Diazgranados et al., 2010a; Zarate et al., 2012; Murrough et al., 2013; Sos et al., 2013), but existing reports and reviews (aan het Rot et al., 2010; Aan Het Rot et al., 2012; Katalinic et al., 2013; Brittner et al., 2014; Caddy et al., 2014; McGirr et al., 2014) do not…”
Cross‐over Trials In Clinical Research
Senn, S. (2002) · doi:10.1002/0470854596 · Cited by 653
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600 · cited 1×
“A key issue is whether the ketamine response can be maintained or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmusse…”
BackgroundDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 10×
“Seven trials (Berman et al., 2000; Zarate et al., 2006, 2012; Diazgranados et al., 2010a; Sos et al., 2013; Lai et al., 2014; Lapidus et al., 2014) used 0.9% saline as placebo and 2 used 0.045 mg/kg (Murrough et al., 2013) or 0.01 mg/kg (C. K. Loo, V. Galvez, E. O’Keefe, unpublished data)…”
BackgroundMethodInfluentialSelf-citationKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386 · cited 1×
“, 2015) and in obsessive compulsive disorder (Rodriguez et al., 2013), and there is encouraging initial evidence comparing ketamine with ECT (Ghasemi et al.”
ResultMcGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373 · cited 2×
“…but existing reports and reviews (aan het Rot et al., 2010; Aan Het Rot et al., 2012; Katalinic et al., 2013; Brittner et al., 2014; Caddy et al., 2014; McGirr et al., 2014) do not easily allow a direct comparison of how treatment effects persist in the days following treatment, given…”
MethodSelf-citationKetamine for rapid reduction of suicidal ideation: a randomized controlled trial
Murrough, J. W., Soleimani, L., DeWilde, K. E., Collins, K. A., Lapidus, K. A., Iacoviello, B. M., Lener, M., Kautz, M., Kim, J., Stern, J. B., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715001506 · Cited by 297 · cited 1×
“Further evidence of reduction in suicidality was recently provided by an additional trial published after our search cut-off date, conducted among 27 patients with mood and anxiety spectrum disorders who presented with clinically significant suicidal ideation.(Murrough et al., 2015) Ketamine may also augment the respo…”
BackgroundSelf-citationZarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Shiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221 · cited 1×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundSerial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 217 · cited 1×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundValentine, G. W., Mason, G. F., Gomez, R., Fasula, M., Watzl, J., Pittman, B., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 204 · cited 1×
“One placebo-controlled trial was not included because the sequence was not randomized (Valentine et al., 2011) and one randomized trial was not included because ketamine was compared with ECT (Ghasemi et al.”
(2013) · PubMed · Cited by 192
Small-Dose Ketamine Improves the Postoperative State of Depressed Patients
Kudoh, A., Takahira, Y., Katagai, H., & Takazawa, T. (2002) · Anesthesia & Analgesia · doi:10.1097/00000539-200207000-00020 · Cited by 189 · cited 1×
“…response pathway can be interrupted in animal models of depression treatment (Autry et al., 2011); and postoperative mood improvement occurs among patients given ketamine intra-operatively, who would have been unaware of immediate subjective effects (Kudoh et al., 2002; Argiriadou et al., 2004).”
BackgroundTakahashi, A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199801000-00048 · Cited by 183
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 161 · cited 7×
“One placebo-controlled trial was not included because the sequence was not randomized (Valentine et al., 2011) and one randomized trial was not included because ketamine was compared with ECT (Ghasemi et al., 2014).”
BackgroundResultInfluentialCaddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313507739 · Cited by 138 · cited 2×
“Data were independently abstracted by 2 reviewers.”
BackgroundKetamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 130 · cited 1×
“, 2013), but existing reports and reviews (aan het Rot et al., 2010; Aan Het Rot et al., 2012; Katalinic et al., 2013; Brittner et al., 2014; Caddy et al., 2014; McGirr et al., 2014) do not easily allow a direct comparison of how treatment effects persist in the days following treatment, given differences in graphical…”
BackgroundSelf-citationPilot dose–response trial of i.v. ketamine in treatment-resistant depression
Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., Harper, S., & Loo, C. K. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.922697 · Cited by 109 · cited 10×
“, 2013); tachycardia (>150 bpm) occurred in 2 patients (Lai et al., 2014); and mean arterial pressure elevations >20% from baseline in 5 patients (Lai et al.”
BackgroundInfluentialSelf-citationPaul, R. H., Schaaff, N., Padberg, F., Möller, H., & Frodl, T. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701714370 · Cited by 106 · cited 1×
“Future trials could also assess ketamine enantiomers (Paul et al., 2009), metabolites (Zarate Jr et al., 2012), or other glutamatergic agents.”
BackgroundDevelopment of a Sublingual/Oral Formulation of Ketamine for Use in Neuropathic Pain
Chong, C., Schug, S. A., Page‐Sharp, M., Jenkins, B., & Ilett, K. F. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00004 · Cited by 93 · cited 1×
“, oral, and sublingual ketamine in chronic pain control (Chong et al., 2009), future longer term trials must assess safety in this patient population.”
BackgroundLarkin, G. L., Beautrais, A. L., Turelli, R. R., Sanacora, G., Powsner, S., Lippmann, M., & Krystal, J. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)73311-9 · Cited by 80
Improvement of Pain Treatment After Major Abdominal Surgery by Intravenous S(+)-Ketamine
Argiriadou, H., Himmelseher, S., Papagiannopoulou, P., Georgiou, M., Kanakoudis, F., Giala, M., & Kochs, E. (2004) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000111204.31815.2d · Cited by 67 · cited 1×
“, 2011); and postoperative mood improvement occurs among patients given ketamine intra-operatively, who would have been unaware of immediate subjective effects (Kudoh et al., 2002; Argiriadou et al., 2004).”
BackgroundRapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 32 · cited 3×
“Aside from electro-convulsive therapy (ECT), there are no widely used treatments that provide large or rapid benefits for patients suffering from severe depression (Martinowich et al., 2013).”
BackgroundInfluentialLa kétamine dans le traitement du trouble dépressif aigu sévère
Brittner, M., Micoulaud‐Franchi, J., Richieri, R. M., Boyer, L., Adida, M., Lançon, C., & Fond, G. B. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2013.11.013 · Cited by 7
Research works printed but not linked: 2
- Aitken, 1969, Measurement of feelings using visual analogue scales, Proc R Soc Med, 62, 989
- RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Cited by
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
“and oxygen saturation or end-tidal CO2; (3) criteria for acceptable baseline vital signs before initiation of medication delivery (eBox 2 in the Supplement); and (4) incorporation of a “time-out” procedure in which the name of the patient and correct dosing parameters are confirmed.”
BackgroundSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Self-citationManagement of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“1,58,89,99 On average, the effects of ketamine appear to come on rapidly and last approximately 5 – 7 days 145 with a preferential treatment effect in individuals with comorbid anxiety or an “ anxious depression ” .”
Metadata
- Authors
- Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., Mitchell, P. B., & Rodgers, A.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Loo, Colleen
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-17
- Volume
- 19
- Issue
- 4
- Pages
- pyv124
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851268
- OpenAlex
- W2197394318
- Cited by
- 226
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 22 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 29 · 2019: 26 · 2018: 28 · 2017: 24 · 2016: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Figshare (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Institute of Mental Health (K23MH104465)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, major depressive disorder, low-dose ketamine, rapid antidepressant effects, dose-response relationship, remission, response rate, suicidality, bipolar disorder, crossover trial, safety and tolerability
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.